SecBot SecBot
SECBOTREPLAY Home › Report › NUVL

NUVL · Nuvalent, Inc

Nuvalent, Inc. · 8-K filed Apr 7, 2026 at 06:33 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 7, 2026 at 06:33 ET

Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This is a key regulatory milestone in the company's oncology pipeline.

  • Nuvalent submitted a New Drug Application (NDA) to the FDA for neladalkib.
  • The drug candidate targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors.
  • The announcement represents a significant advancement in the company's clinical development program.
  • No financial figures or timelines for FDA decision were disclosed in the filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access